Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic
Nguyen, Thanh N; Haussen, Diogo C; Qureshi, Muhammad M; Yamagami, Hiroshi; Fujinaka, Toshiyuki; Mansour, Ossama Y; Abdalkader, Mohamad; Frankel, Michael; Qiu, Zhongming; Taylor, Allan; Lylyk, Pedro; Eker, Omer F; Mechtouff, Laura; Piotin, Michel; Lima, Fabricio Oliveira; Mont'Alverne, Francisco; Izzath, Wazim; Sakai, Nobuyuki; Mohammaden, Mahmoud; Al-Bayati, Alhamza R; Renieri, Leonardo; Mangiafico, Salvatore; Ozretic, David; Chalumeau, Vanessa; Ahmad, Saima; Rashid, Umair; Hussain, Syed Irteza; John, Seby; Griffin, Emma; Thornton, John; Fiorot, Jose Antonio; Rivera, Rodrigo; Hammami, Nadia; Cervantes-Arslanian, Anna M; Dasenbrock, Hormuzdiyar H; Vu, Huynh Le; Nguyen, Viet Quy; Hetts, Steven; Bourcier, Romain; Guile, Romain; Walker, Melanie; Sharma, Malveeka; Frei, Don; Jabbour, Pascal; Herial, Nabeel; Al-Mufti, Fawaz; Ozdemir, Atilla Ozcan; Aykac, Ozlem; Gandhi, Dheeraj; Chugh, Chandril; Matouk, Charles; Lavoie, Pascale; Edgell, Randall; Beer-Furlan, Andre; Chen, Michael; Killer-Oberpfalzer, Monika; Pereira, Vitor Mendes; Nicholson, Patrick; Huded, Vikram; Ohara, Nobuyuki; Watanabe, Daisuke; Shin, Dong Hun; Magalhaes, Pedro Sc; Kikano, Raghid; Ortega-Gutierrez, Santiago; Farooqui, Mudassir; Abou-Hamden, Amal; Amano, Tatsuo; Yamamoto, Ryoo; Weeks, Adrienne; Cora, Elena A; Sivan-Hoffmann, Rotem; Crosa, Roberto; Möhlenbruch, Markus; Nagel, Simon; Al-Jehani, Hosam; Sheth, Sunil A; Lopez Rivera, Victor S; Siegler, James E; Sani, Achmad Fidaus; Puri, Ajit S; Kuhn, Anna Luisa; Bernava, Gianmarco; Machi, Paolo; Abud, Daniel G; Pontes-Neto, Octavio M; Wakhloo, Ajay K; Voetsch, Barbara; Raz, Eytan; Yaghi, Shadi; Mehta, Brijesh P; Kimura, Naoto; Murakami, Mamoru; Lee, Jin Soo; Hong, Ji Man; Fahed, Robert; Walker, Gregory; Hagashi, Eiji; Cordina, Steve M; Roh, Hong Gee; Wong, Ken; Arenillas, Juan F; Martinez-Galdamez, Mario; Blasco, Jordi; Rodriguez Vasquez, Alejandro; Fonseca, Luisa; Silva, M Luis; Wu, Teddy Y; John, Simon; Brehm, Alex; Psychogios, Marios; Mack, William J; Tenser, Matthew; Todaka, Tatemi; Fujimura, Miki; Novakovic, Roberta; Deguchi, Jun; Sugiura, Yuri; Tokimura, Hiroshi; Khatri, Rakesh; Kelly, Michael; Peeling, Lissa; Murayama, Yuichi; Winters, Hugh Stephen; Wong, Johnny; Teleb, Mohamed; Payne, Jeremy; Fukuda, Hiroki; Miyake, Kosuke; Shimbo, Junsuke; Sugimura, Yusuke; Uno, Masaaki; Takenobu, Yohei; Matsumaru, Yuji; Yamada, Satoshi; Kono, Ryuhei; Kanamaru, Takuya; Morimoto, Masafumi; Iida, Junichi; Saini, Vasu; Yavagal, Dileep; Bushnaq, Saif; Huang, Wenguo; Linfante, Italo; Kirmani, Jawad; Liebeskind, David S; Szeder, Viktor; Shah, Ruchir; Devlin, Thomas G; Birnbaum, Lee; Luo, Jun; Churojana, Anchalee; Masoud, Hesham E; Lopez, Carlos Ynigo; Steinfort, Brendan; Ma, Alice; Hassan, Ameer E; Al Hashmi, Amal; McDermott, Mollie; Mokin, Maxim; Chebl, Alex; Kargiotis, Odysseas; Tsivgoulis, Georgios; Morris, Jane G; Eskey, Clifford J; Thon, Jesse; Rebello, Leticia; Altschul, Dorothea; Cornett, Oriana; Singh, Varsha; Pandian, Jeyaraj; Kulkarni, Anirudh; Lavados, Pablo M; Olavarria, Veronica V; Todo, Kenichi; Yamamoto, Yuki; Silva, Gisele Sampaio; Geyik, Serdar; Johann, Jasmine; Multani, Sumeet; Kaliaev, Artem; Sonoda, Kazutaka; Hashimoto, Hiroyuki; Alhazzani, Adel; Chung, David Y; Mayer, Stephan A; Fifi, Johanna T; Hill, Michael D; Zhang, Hao; Yuan, Zhengzhou; Shang, Xianjin; Castonguay, Alicia C; Gupta, Rishi; Jovin, Tudor G; Raymond, Jean; Zaidat, Osama O; Nogueira, Raul G
BACKGROUND:During the COVID-19 pandemic, decreased volumes of stroke admissions and mechanical thrombectomy were reported. The study's objective was to examine whether subarachnoid haemorrhage (SAH) hospitalisations and ruptured aneurysm coiling interventions demonstrated similar declines. METHODS:We conducted a cross-sectional, retrospective, observational study across 6 continents, 37 countries and 140 comprehensive stroke centres. Patients with the diagnosis of SAH, aneurysmal SAH, ruptured aneurysm coiling interventions and COVID-19 were identified by prospective aneurysm databases or by International Classification of Diseases, 10th Revision, codes. The 3-month cumulative volume, monthly volumes for SAH hospitalisations and ruptured aneurysm coiling procedures were compared for the period before (1 year and immediately before) and during the pandemic, defined as 1 March-31 May 2020. The prior 1-year control period (1 March-31 May 2019) was obtained to account for seasonal variation. FINDINGS/RESULTS:There was a significant decline in SAH hospitalisations, with 2044 admissions in the 3 months immediately before and 1585 admissions during the pandemic, representing a relative decline of 22.5% (95% CI -24.3% to -20.7%, p<0.0001). Embolisation of ruptured aneurysms declined with 1170-1035 procedures, respectively, representing an 11.5% (95%CI -13.5% to -9.8%, p=0.002) relative drop. Subgroup analysis was noted for aneurysmal SAH hospitalisation decline from 834 to 626 hospitalisations, a 24.9% relative decline (95% CI -28.0% to -22.1%, p<0.0001). A relative increase in ruptured aneurysm coiling was noted in low coiling volume hospitals of 41.1% (95% CI 32.3% to 50.6%, p=0.008) despite a decrease in SAH admissions in this tertile. INTERPRETATION/CONCLUSIONS:There was a relative decrease in the volume of SAH hospitalisations, aneurysmal SAH hospitalisations and ruptured aneurysm embolisations during the COVID-19 pandemic. These findings in SAH are consistent with a decrease in other emergencies, such as stroke and myocardial infarction.
PMCID:8006491
PMID: 33771936
ISSN: 2059-8696
CID: 4830292
Development of Novel CAR Therapies for Diffuse Large B-Cell Lymphoma Using Genome-Wide Overexpression Screens [Meeting Abstract]
Legut, M; Gajic, Z; Guarino, M; Mimitou, E; Hao, S; Rahman, J; Davoli, T; Smibert, P; Diefenbach, C S; Sanjana, N
Despite recent therapeutic advances in the management of non-Hodgkin lymphoma (NHL), up to 50% of patients with diffuse large B-cell lymphoma (DLBCL) relapse after first line therapy, and for DLBCL patients who relapse within 12 months after subsequent stem cell transplant (SCT), the median overall survival (OS) is 6.3 months. Recently, chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in relapsed DLBCL with complete response (CR) rate of 40% and 54% for the two of the FDA-approved CAR T-cell products, tisagenlecleucel and axicabtagene ciloleucel, respectively. However, at a median follow-up of 18 months, only 36% of patients treated with tisagenlecleucel remained in CR; with longer follow-up for axicabtagene ciloleucel the median progression free survival (PFS) was 5.9 months. Immune escape and immune evasion are primary mechanisms of CAR-T resistance; clearly improvements are needed to increase response rate and cure. While CRISPR-based loss-of-function screens have shown promise for high-throughput identification of genes that modulate T-cell response, these methods have been limited thus far to negative regulators of T-cell functions, and raise safety concerns due to the permanent nature of genome modification. Here we identify positive T-cell regulators via overexpression of ~12,000 barcoded human open reading frames (ORFs). Using this genome-scale ORF screen, we found modulator genes which increased primary human CD4+ and CD8+ T-cell proliferation, including activation markers like CD25 and CD40L, and secretion of key cytokines like interleukin-2 and interferon-gamma. In addition, we developed a single-cell genomics method (OverCITE-seq) for high-throughput quantification of the transcriptome and surface proteome in ORF-engineered T-cells. The top-ranked ORF, lymphotoxin beta receptor (LTBR), is typically expressed in a subset of myeloid cells but absent in lymphocytes. When expressed in T-cells, LTBR induces a profound transcriptional remodelling, resulting in increased resistance to exhaustion and activation-induced apoptosis, as well as upregulation of a plethora of proinflammatory cytokines, co-stimulatory molecules and antigen presentation machinery. In order to investigate the mechanism of action of LTBR, we developed an epistasis assay which allows for simultaneous gene knockout and LTBR overexpression in primary T cells. Thus, LTBR appears to induce both canonical and non-canonical NFkB pathways - but the phenotype observed in T cells is dependent only on the former. Finally, we co-expressed several top-ranked genes, including LTBR, with FDA approved CD19-targeting CARs utilizing either 4-1BB or CD28 co-stimulatory domains. In line with previous results, co-expression of top-ranked ORFs increased proinflammatory cytokine secretion and cytotoxicity against CD19+ positive cancer cell lines. This functional improvement was also observed when top-ranked ORFs and CARs were delivered to T cells isolated from DLBCL patients as shown in Figure 1. Our results provide several strategies for improving next generation CAR T-cell therapies via induction of new synthetic cell programs which may optimize immune activation and enhance the efficacy of these important therapies, a high priority for patients with relapsed and refractory DLBCL and other lymphomas. [Formula presented] Disclosures: Mimitou: Immunai: Current Employment. Smibert: Immunai: Current Employment. Diefenbach: Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; IMab: Research Funding; Gilead: Current equity holder in publicly-traded company; Celgene: Research Funding; AbbVie: Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Merck Sharp & Dohme: Consultancy, Honoraria, Research Funding; IGM Biosciences: Research Funding; Morphosys: Consultancy, Honoraria, Research Funding; MEI: Consultancy, Research Funding; Perlmutter Cancer Center at NYU Langone Health: Current Employment; Incyte: Research Funding; Trillium: Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Genentech, Inc./ F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding. Sanjana: Qiagen: Consultancy; Vertex: Consultancy.
Copyright
EMBASE:2016079578
ISSN: 0006-4971
CID: 5098712